IPR Center, Amazon Launch ‘Operation Fulfilled Action’ to Stop Counterfeits

IPR Center, Amazon Launch ‘Operation Fulfilled Action’ to Stop Counterfeits

WASHINGTON–(BUSINESS WIRE)–
The U.S. government’s National Intellectual Property Rights Coordination Center (IPR Center) and Amazon today announced the launch of a joint operation to prevent counterfeit goods from entering the U.S. and help protect American consumers. U.S. Customs and Border Protection (CBP) and DHL are also supporting the operation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201124005382/en/

“The IPR Center plays a critical role in securing the global supply-chain to protect the health and safety of the American public,” said IPR Center Director Steve Francis. “However, our efforts are increased with partners like Amazon to identify, interdict, and investigate individuals, companies, and criminal organizations engaging in the illegal importation of counterfeit products. This joint operation is our latest public-private initiative bringing us one step closer to border security.”

“Amazon conducts investigations and sidelines inventory if we suspect a product may be counterfeit, ensuring our customers are protected,” said Dharmesh Mehta, vice president, Customer Trust and Partner Support, Amazon. “But we also know that counterfeiters don’t just attempt to offer their wares in one store, they attempt to offer them in multiple places. Now, by combining intelligence from Amazon, the IPR Center, and other agencies, we’re able to stop counterfeits at the border, regardless of where bad actors were intending to offer them. We appreciate the partnership from the IPR Center and other agencies to protect American consumers and prosecute bad actors.”

In an effort to protect consumers, this joint operation will analyze data and conduct targeted inspections aimed at preventing counterfeit products from entering the U.S. supply chain. The IPR Center and Amazon will leverage evidence obtained during the operation to expand on-going investigations, with the goal of holding bad actors accountable to the fullest extent of the law.

This operation will be led by Amazon’s Counterfeit Crimes Unit, which was created earlier this year to support law enforcement investigations and to initiate civil litigation against counterfeiters.

Amazon strictly prohibits the sale of counterfeit products, and in 2019 alone, invested more than $500 million to protect its store and customers from counterfeit and other forms of fraud and abuse. These investments include machine learning and automated systems to detect bad actors and potentially counterfeit products, dedicated teams to operate and continually refine its anti-counterfeiting programs, and tools that help Amazon work with and empower brands. As a result, 99.9% of pages viewed by customers on Amazon did not receive a valid counterfeit complaint and customers continue to shop with confidence on Amazon.

This operation builds on longstanding strategic public-private initiatives currently in place at the IPR Center. Amazon proactively provides the IPR Center with data on confirmed counterfeiters to assist with investigative efforts to stop crime. More recently in May, Amazon was one of six industry leaders to join the IPR Center in an unprecedented public-private partnership to combat fraud and other illegal activity related to COVID-19 through Operation Stolen Promise (OSP). OSP is a joint task force focused on combating COVID-19 related fraud and criminal activity.

The IPR Center is one of the U.S. government’s key weapons in the fight against criminal counterfeiting and piracy. The center uses the expertise of 25 key federal and international agencies to share information, develop initiatives, coordinate enforcement actions, and conduct investigations related to IP theft and commercial fraud crimes.

About National Intellectual Property Rights Coordination Center

The National Intellectual Property Rights Coordination Center, working collaboratively with its public and private sector partners, stands at the forefront of the United States government’s response to combatting global intellectual property theft and enforcing intellectual properties rights violations. The IPR Center was established to combat global intellectual property theft – and, accordingly, has a significant role policing the sale and distribution of counterfeit goods on websites, social media, and the dark web. To report IP theft or to learn more about the IPR Center, visit www.IPRCenter.gov.

About Amazon

Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.

Amazon.com, Inc.

Media Hotline

[email protected]

www.amazon.com/pr

KEYWORDS: United States North America District of Columbia

INDUSTRY KEYWORDS: Supply Chain Management Online Retail Law Enforcement/Emergency Services Retail Public Policy/Government

MEDIA:

Logo
Logo
Logo
Logo

Wizard Brands, Inc. Appoints Scott D. Kaufman Chairman and Chief Executive Officer and Heidi C. Bowman as CFO; Mike Rees Appointed CEO of Jevo Holdings, LLC; Peter Katz Appointed President Of Wizard Special Events, LLC

Wizard Brands, Inc. Appoints Scott D. Kaufman Chairman and Chief Executive Officer and Heidi C. Bowman as CFO; Mike Rees Appointed CEO of Jevo Holdings, LLC; Peter Katz Appointed President Of Wizard Special Events, LLC

LOS ANGELES–(BUSINESS WIRE)–
Wizard Brands, Inc. (OTCBB WIZD) today announced the appointment of Scott Kaufman as Chairman and Chief Executive Officer. The Company also announced that finance and accounting executive Heidi C. Bowman has been appointed CFO for Wizard Brands, Inc. and distribution executive Mike Rees will take over as CEO of Jevo Holdings, LLC, a wholly-owned subsidiary of Wizard Brands, Inc..

“Scott Kaufman brings to Wizard Brands his solid business experience and proven success in corporate finance and strategic operational and financial development. With Scott’s experienced leadership and knowledge in guiding companies on the path to financial success, Wizard Brands is poised to expand its already significant footprint. Scott will work with us to guide the company through its next phase of growth and beyond. Mike Rees, with his years of operating experience as a distributor, will expertly guide the Jevo unit,” said Paul Kessler, Chairman of the Wizard Brands Board of Directors.

Jevo Holdings, LLC, a wholly-owned subsidiary of Wizard Brands, Inc. will be overseen by CEO Michael R. Rees, who has spent the better part of his career in the private business sector launching and building innovative companies with extensive experience in distribution. Mr. Rees’ expertise includes creating and managing distributorships and the managing and training of sales and marketing teams.

Jevo Holdings, LLC manufactures, markets and distributes the patented ‘JEVO’ Automated Gelatin Shot Maker for various applications in the hospitality, skilled nursing, pharmaceuticals, health, and cannabis segments. A consumer unit of the ‘Jevo’ machine is in the initial phases of research and development.

Wizard Special Events LLC, a wholly-owned subsidiary of Wizard Brands, Inc., operates Wizard World Virtual, Wizard World Vault, and Wizard World pop culture festivals. Peter Katz has been named President, and Joseph Avino has been named Executive Vice President, of Wizard Special Events, LLC. Both Mr. Katz and Mr. Avino are experienced long-tenured executives in the exhibition industry.

Scott D. Kaufman, currently an Independent Director at Wizard Brands, Inc., and a founding member of Barlock Capital Management LLC and Hillair Capital Management LLC, will continue his role at Bristol Capital Advisors in the capacity of Institutional Investor in Residency. Mr. Kaufman has over twenty years of experience investing in private and public companies, trading securities and managing investment portfolios. Mr. Kaufman received his undergraduate degree from Columbia University and an MBA from Columbia University.

Joining Mr. Kaufman in the executive management of Wizard Brands, Inc. is Heidi C. Bowman, who has been appointed as CFO. Ms. Bowman brings with over 30 years of finance and accounting experience in a variety of industries including private equity, oil & gas and real estate. Ms. Bowman received her undergraduate degree from UCLA in Economics.

Wizard Brands, Inc., is a dynamic and multi-faceted holding company comprised of growing brands, led by a management team with proven success and experience tasked with the execution of a twofold strategy: (i) continue to execute on the business plan of the wholly-owned operating companies while growing and enhancing its business operations and financial position, (ii) pursue opportunities to acquire complementary businesses that will create value for Wizard Brands customer base and stakeholders. Current Executive Chairman Paul Kessler and current CEO John D. Maatta will remain as members of the Wizard Brands, Inc. Board of Directors. The appointments of Mr. Kaufman, Ms. Bowman, Mr. Rees and Mr. Katz and Mr. Avino are effective as of November 24, 2020.

Jerry Milani

[email protected]

646-883-5022

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Professional Services Entertainment Other Professional Services Other Entertainment General Entertainment Finance Accounting

MEDIA:

Logo
Logo

Legend Biotech to Host Virtual Investor KOL Event Reviewing Latest CARTITUDE-1 Data from the 62nd American Society of Hematology (ASH) Annual Meeting

Legend Biotech to Host Virtual Investor KOL Event Reviewing Latest CARTITUDE-1 Data from the 62nd American Society of Hematology (ASH) Annual Meeting

SOMERSET, N.J.–(BUSINESS WIRE)–
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech) today announced that it will host a virtual Key Opinion Leader (KOL) event on Monday, December 7 at 7 pm ET highlighting the latest data from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) of ciltacabtagene autoleucel (cilta-cel), an investigational BCMA-directed CAR-T cell therapy being studied for the treatment of patients with relapsed or refractory multiple myeloma. This will follow the oral presentation of the study results (Abstract #177) at the 2020 ASH Annual Meeting.

Intended for investors and other interested audiences, the event includes presentations by Ying Huang, PhD, CEO and CFO of Legend Biotech, along with the following leading professionals in hematology and oncology:

  • Sundar Jagannath, MD, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine; Director, Multiple Myeloma Program at Mount Sinai Hospital.
  • Thomas G. Martin, MD, Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program, and Associate Director, Myeloma Program, UCSF; Co-Leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center.

To register and to view the live webcast, please visit: LegendBiotechASH2020.Convene.com.

About CARTITUDE-1

Cilta-cel is currently being investigated in the Phase 1b/2 CARTITUDE-1 (MMY2001, NCT03548207) registration study conducted in the US and Japan for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy or are double refractory to a PI and IMiD®, received a PI, an IMiD, and anti-CD38 antibody and documented disease progression within 12 months of starting the most recent therapy.

About Cilta-cel

Cilta-cel is an investigational chimeric antigen receptor T (CAR-T) cell therapy, formerly identified as JNJ-4528 in the U.S. and Europe and LCAR-B38M in China, that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and in earlier lines of treatment. The design consists of a structurally differentiated CAR-T with two BCMA-targeting single domain antibodies. In December 2017, Legend Biotech, Inc. entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize cilta-cel. In addition to a Breakthrough Therapy Designation (BTD) granted in the U.S. in December 2019, cilta-cel received a PRIority MEdicines (PRiME) designation from the European Commission in April 2019 and BTD in China in August 2020. In addition, Orphan Drug Designation was granted for cilta-cel by the U.S. FDA in February 2019, and by the European Commission in February 2020.

About Legend Biotech

Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 800 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture cutting-edge cell therapies for patients in need. We are engaged in a strategic collaboration to develop and commercialize our lead product candidate, ciltacabtagene autoleucel, an investigational BCMA targeted CAR-T cell therapy for patients with multiple myeloma. This candidate is currently being studied in registrational clinical trials. To learn more about Legend Biotech, visit us on LinkedIn, or on Twitter @LegendBiotech or at www.legendbiotech.com.

Cautions Concerning Forward-Looking Statements

This information constitutes forward-looking statements relating to the business of Legend, including express or implied discussions regarding the clinical development of its product candidates and potential attributes and benefits of such product candidates. Such forward-looking statements reflect the current views of Legend’s management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, Legend’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; Legend’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing and other political pressures. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

The safety and efficacy of the product candidates and/or uses under investigation have not been established. There is no guarantee that the product candidates will receive health authority approval or become commercially available in any country for the uses being investigated.

The information in this press release speaks only as of the date hereof. Legend assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date.

For Media and Investor Relations inquiries, please contact:

Jessie Yeung, Head of Corporate Finance and Investor Relations, Legend Biotech

[email protected] or [email protected]

Surabhi Verma, Manager of Investor Relations and Corporate Communications, Legend Biotech

[email protected] or [email protected]

For Medical Affairs inquiries, please contact:

Tonia Nesheiwat, Executive Director, Medical Affairs, Legend Biotech

[email protected] or [email protected]

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Oncology Health Hospitals Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

Guidewire Software to Announce First Quarter Fiscal 2021 Financial Results on December 8, 2020

Guidewire Software to Announce First Quarter Fiscal 2021 Financial Results on December 8, 2020

SAN MATEO, Calif.–(BUSINESS WIRE)–
Guidewire Software, Inc. (NYSE: GWRE), the platform Property & Casualty (P&C) insurers trust to engage, innovate, and grow efficiently, today announced that it will release its financial results for the fiscal quarter ended October 31, 2020 after market close on Tuesday, December 8, 2020. On that day, management will hold a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to review and discuss the Company’s results for the first quarter 2021. A recorded version of this webcast will be available two hours after the call and accessible at http://ir.guidewire.com.

What:

Guidewire Software First Quarter Fiscal 2021 Financial Results Conference Call

When:

Tuesday, December 8, 2020

Time:

2:00 p.m. PT (5:00 p.m. ET)

Live Call:

(877) 705-6003, Domestic

 

(201) 493-6725, International

Replay:

(844) 512-2921, Passcode 13713614, Domestic

 

(412) 317-6671, Passcode 13713614, International

Webcast:

http://ir.guidewire.com/ (live and replay)

The webcast will be archived on Guidewire’s website for a period of three months.

About Guidewire Software

Guidewire is the platform P&C insurers trust to engage, innovate, and grow efficiently. We combine digital, core, analytics, and AI to deliver our platform as a cloud service. More than 400 insurers, from new ventures to the largest and most complex in the world, run on Guidewire.

As a partner to our customers, we continually evolve to enable their success. We are proud of our unparalleled implementation track record, with 1,000+ successful projects, supported by the largest R&D team and partner ecosystem in the industry. Our marketplace provides hundreds of applications that accelerate integration, localization, and innovation.

For more information, please visitwww.guidewire.com and follow us on twitter: @Guidewire_PandC.

NOTE: For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices.

Investor Relations Contact:

Garo Toomajanian

ICR, LLC

+1 (650) 357 5282

[email protected]

Media Contact:

Diana Stott

Guidewire Software, Inc.

+1 (650) 356 4941

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Data Management Professional Services Technology Insurance Software

MEDIA:

CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020, at 9:30 a.m. ET.

A live webcast of the event will be available on the “Events & Presentations” page in the Investors section of the Company’s website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company’s website for 14 days following the presentation.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:

Susan Kim
+1-617-307-7503
[email protected]

Media Contact:

Rachel Eides
WCG on behalf of CRISPR
+1-617-337-4167
[email protected]

 



iCAD Reports Over 1,000 Licenses Sold as Part of ProFound AI Sales


Significant Percentage


of Licenses


Sold to Facilities with GE, Siemens, and Sites with Multiple Vendors Including Hologic and


Fuji


ProFound AI


for DBT Offers


Superior


Clinical


Performance


When Compared to Other Commercially Available Breast AI Systems

NASHUA, N.H., Nov. 24, 2020 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported that over 1,000 licenses have been sold as part of ProFound AI® sales since the products were launched, signaling the rapid and wide-spread adoption of the pioneering cancer detection software solution built on artificial intelligence (AI). The sales have been distributed across all major mammography system vendors and enterprise-wide viewing applications with a significant percentage to date sold to hospitals and imaging centers with GE and Siemens, as well as facilities with more than one imaging system vendor, including Hologic and Fuji.

The solid momentum is led by the Company’s growing customer base and demand for its expanded suite of leading breast health AI solutions, including ProFound AI for both Digital Breast Tomosynthesis (DBT) and 2D mammography, and interest in the recently introduced ProFound AI Risk, which is helping to transform breast cancer screening from age-based screening to risk-adapted precision screening, individualized for each woman.

“iCAD offers the full continuum of breast health AI products—both for the detection of current breast cancers and for future risk assessment,” said Michael Klein, Chairman and CEO of iCAD. “We do so on a non-exclusive, open architecture basis, therefore allowing all global customers access to the best of breed AI software available. Of significant note is that no other breast AI solution has been shown to improve radiologists’ clinical performance when reading DBT more so than ProFound AI. Specifically, our high-performing cancer detection and workflow solution offers the highest cancer detection rate, the lowest false positive rate and a dramatic 52.7% reduction in radiologists’ reading time, representing a high level of clinical significance and advantage.”

According to Kathy Schilling, MD, Medical Director of the Christine E. Lynn Women’s Health & Wellness Institute at the Boca Raton Regional Hospital, “ProFound AI for DBT rapidly and accurately analyze patients’ DBT mammography images, identifying suspicious lesions and producing quantifiable AI scores, which enables us to identify cancers earlier. The software also improves workflow issues, as we’re able to more quickly navigate through DBT datasets.”

ProFound AI Risk is the first and only commercially available clinical decision support tool to provide an accurate two-year breast cancer risk estimation based solely on a screening mammogram. Compelling research published in the peer-reviewed journal, Radiology concluded that the ProFound AI Risk model is effective at identifying women at high likelihood of being diagnosed with breast cancer within two years of a negative screening mammogram and in possible need of supplemental screening.

“I was very enthusiastic about the launch of ProFound AI Risk, which I believe is more accurate than the other risk tools I’ve used, and it is very easy to integrate into my daily workflow,” said Carine Van De Merckt, MD, Radiologist at Institut Jules Bordet in Brussels, Belgium. “Furthermore, it has proven to help me in my clinical decision making, allowing me to continue to provide the best care to my patients with even more confidence.”

As part of the Company’s growth, iCAD has recently achieved significant milestones, including:

  • Sequential Revenue Growth of 44% in Third Quarter: The Company realized significant revenue growth over the second quarter in 2020, particularly with its innovative ProFound AI product offerings, which grew 44%.
  • Strong International Growth: The Company, with products now distributed in 22 countries outside the U.S., recently signed distribution agreements in Switzerland and Portugal. The first ProFound AI for DBT sold in the United Kingdom and the first ProFound AI Risk sold in Belgium both occurred in October 2020.
  • Distribution Agreement with Change Healthcare: A new agreement with the leading independent healthcare technology company, Change Healthcare, enhances commercial access to enterprise imaging and integrated delivery system networks throughout the U.S.

According to Change Healthcare’s Tracy Byers, Senior Vice President and General Manager of Imaging, as Change Healthcare looks to accelerate and transform enterprise imaging with the use of AI and cloud-native solutions, the partnership with iCAD enables them to offer their customers the ProFound AI platform as part of their Mammography Plus offering. “We are focused on radiologist productivity and aiding them with decision support tools that are elegantly integrated into their workflow,” said Byers. “The integration of iCAD’s AI solutions into our digital mammography platform will help improve patient outcomes by improving early cancer detection and enhancing clinical workflow. We could not be more excited about empowering our customers and our new partnership with iCAD.”

“iCAD’s momentum underscores the increasing demand for our comprehensive breast health AI solutions for DBT, breast density, and 2D mammography, offering clinicians a broad range of powerful tools for early disease detection and optimized reading workflow that results in improved patient outcomes,” said Stacey Stevens, president at iCAD. “This, coupled with ProFound AI’s seamless integration with major PACS for decision support capabilities across large networks, and ProFound AI’s compatibility with all leading mammography systems, allows hospitals and imaging centers with one or multi-vendor imaging systems to have a proven, standardized AI solution.

“Moreover, our principal approach to transforming breast cancer detection and care is best illustrated by our panoramic vision—to provide a more holistic view of each patient’s current imaging exam, history, and short-term risk,” continued Stevens. “With the addition of ProFound AI Risk, we intend to move mammography from primarily an age-based screening paradigm to a risk-adjusted precision screening paradigm that is truly personalized for every woman.”

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.

ProFound AI for DBT is proven to curtail workflow challenges substantially by reducing radiologists’ reading time by 52.7%, thereby reducing by half the amount of time it takes radiologists to read 3D mammography datasets. Additionally, the platform improved radiologists’ performance measured by Area Under the Curve (AUC) by nearly 6% and reduced unnecessary patient recall rates by more than 7%.i

ProFound AI Risk is currently available on an introductory basis for 2D mammography and will subsequently be available for the rapidly growing 3D mammography market.

For more information, visit www.icadmed.com and www.xoftinc.com

Forward-Looking Statements

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians,  the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights,  product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

Media Inquiries:

Amy Cook, iCAD
+1 (925) 200-2125
[email protected]

Investor Relations:

Jeremy Feffer, LifeSci Advisors
+1 (212) 915-2568
[email protected]

__________________________

i Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096



Analog Devices Reports Fourth Quarter Results Above the High-End of Outlook

Analog Devices Reports Fourth Quarter Results Above the High-End of Outlook

  • Revenue of $1.53 billion for the fourth quarter and $5.60 billion for fiscal 2020
  • B2B revenue for the fourth quarter increased 4% sequentially and 10% year-over-year
  • Operating cash flow of $2.0 billion and free cash flow of $1.8 billion for fiscal 2020
  • Returned over $1.1 billion to shareholders in fiscal 2020 and recently reinstated our buyback program

WILMINGTON, Mass.–(BUSINESS WIRE)–
Analog Devices, Inc. (Nasdaq: ADI), a leading global high-performance semiconductor company, today announced financial results for its fourth quarter and full year fiscal 2020, which ended October 31, 2020.

“ADI delivered fourth quarter results above the high-end of our outlook. We grew revenue across all of our B2B markets, expanded operating margins and increased EPS by double-digits year-over-year,” said Vincent Roche, President and CEO of Analog Devices. “Fiscal 2020 represented a year of strategic progress against an unprecedented backdrop, and our results continue to highlight the insatiable demand for our high-performance analog and mixed signal solutions. Overall, I’m proud of how our global team embraced and learned from this challenging time and continued to execute at a high level to generate and capture value for all stakeholders.”

Roche continued, “Looking ahead, our pending acquisition of Maxim Integrated is an opportunity to increase our scale and scope to deliver disruptive innovation for our customers while driving further profitable growth. The combination strengthens our industry leadership position, further diversifying our business across markets and applications and solidifying ADI as the destination for the world’s best analog talent. While the macroenvironment remains fluid, we are cautiously optimistic that a broad-based recovery is underway and expect to build on this momentum in fiscal 2021.”

Performance for the Fourth Quarter of Fiscal 2020

Results Summary(1)

 

 

 

 

 

(in millions, except per-share amounts and percentages)

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Oct 31, 2020

 

Nov 2, 2019

 

Change

Revenue

$

1,526

 

 

$

1,443

 

 

6

%

Gross margin

$

1,023

 

 

$

942

 

 

9

%

Gross margin percentage

67.0

%

 

65.3

%

(2)

 

170 bps

Operating income

$

462

 

 

$

338

 

 

36

%

Operating margin

30.2

%

 

23.4

%

 

680 bps

Diluted earnings per share

$

1.04

 

 

$

0.74

 

 

41

%

 

 

 

 

 

 

Adjusted Results

 

 

 

 

 

Adjusted gross margin

$

1,068

 

 

$

987

 

 

8

%

Adjusted gross margin percentage

70.0

%

 

68.4

%

(2)

 

160 bps

Adjusted operating income

$

636

 

 

$

560

 

 

14

%

Adjusted operating margin

41.7

%

 

38.8

%

 

290 bps

Adjusted diluted earnings per share

$

1.44

 

 

$

1.19

 

 

21

%

 

 

 

 

 

 

 

 

 

Three Months

Ended

 

Trailing Twelve

Months

Cash Generation

 

 

Oct 31, 2020

 

Oct 31, 2020

Net cash provided by operating activities

 

 

$

673

 

 

$

2,008

 

% of revenue

 

 

44.1

%

 

35.8

%

Capital expenditures

 

 

$

(30)

 

 

$

(166)

 

Free cash flow

 

 

$

643

 

 

$

1,843

 

% of revenue

 

 

42.1

%

 

32.9

%

 

 

 

 

 

 

 

 

 

Three Months

Ended

 

Trailing Twelve

Months

Cash Return

 

 

Oct 31, 2020

 

Oct 31, 2020

Dividend paid

 

 

$

(230)

 

 

$

(886)

 

Stock repurchases

 

 

(7)

 

 

(244)

 

Total cash returned

 

 

$

(237)

 

 

$

(1,131)

 

(1) The sum and/or computation of the individual amounts may not equal the total due to rounding.

(2) Includes approximately 140 basis points of impact from a write-down of inventory associated with a customer within our Communications end market.

Outlook for the First Quarter of Fiscal Year 2021

For the first quarter of fiscal 2021, we are forecasting revenue of $1.50 billion, +/- $70 million. At the midpoint of this revenue outlook, we expect reported operating margin of approximately 29.1%, +/- 150 bps, and adjusted operating margin of approximately 40.0%, +/- 100 bps. We are planning for reported EPS to be $0.92, +/- $0.10, and adjusted EPS to be $1.30, +/- $0.10.

Our first quarter fiscal 2021 outlook is based on current expectations and actual results may differ materially, as a result of, among other things, the important factors discussed at the end of this release. These statements supersede all prior statements regarding our business outlook set forth in prior ADI news releases, and ADI disclaims any obligation to update these forward-looking statements.

The adjusted results and adjusted anticipated results above are financial measures presented on a non-GAAP basis. Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP financial measures are provided in the financial tables included in this press release. See also “Non-GAAP Financial Information” section for additional information.

Dividend Payment

The ADI Board of Directors has declared a quarterly cash dividend of $0.62 per outstanding share of common stock. The dividend will be paid on December 15, 2020 to all shareholders of record at the close of business on December 4, 2020.

Conference Call Scheduled for Today, Tuesday, November 24, 2020 at 10:00 am ET

ADI will host a conference call to discuss our fourth quarter fiscal 2020 results and short-term outlook today, beginning at 10:00 am ET. Investors may join via webcast, accessible at investor.analog.com, or by telephone (call 800-859-9560, or 706-634-7193 for international calls, ten minutes before the call begins and provide the password “ADI”).

A replay will be available two hours after the completion of the call. The replay may be accessed for up to two weeks by dialing 855-859-2056 (replay only) and providing the conference ID: 5297321, or by visiting investor.analog.com.

Non-GAAP Financial Information

This release includes non-GAAP financial measures that are not in accordance with, nor an alternative to, generally accepted accounting principles (GAAP) and may be different from non-GAAP measures presented by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. These non-GAAP measures have material limitations in that they do not reflect all of the amounts associated with the Company’s results of operations as determined in accordance with GAAP and should not be considered in isolation from, or as a substitute for, the Company’s financial results presented in accordance with GAAP. The Company’s use of non-GAAP measures, and the underlying methodology when including or excluding certain items, is not necessarily an indication of the results of operations that may be expected in the future, or that the Company will not, in fact, record such items in future periods. You are cautioned not to place undue reliance on these non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP are provided in the financial tables included in this release.

Management uses non-GAAP measures internally to evaluate the Company’s operating performance from continuing operations against past periods and to budget and allocate resources in future periods. These non-GAAP measures also assist management in evaluating the Company’s core business and trends across different reporting periods on a consistent basis. Management also uses these non-GAAP measures as the primary performance measurement when communicating with analysts and investors regarding the Company’s earnings results and outlook and believes that the presentation of these non-GAAP measures is useful to investors because it provides investors with the operating results that management uses to manage the Company and enables investors and analysts to evaluate the Company’s core business. Management also believes that the non-GAAP liquidity measure free cash flow is useful both internally and to investors because it provides information about the amount of cash generated after capital expenditures that is then available to repay debt obligations, make investments and fund acquisitions, and for certain other activities.

The non-GAAP financial measures referenced by ADI in this release include: adjusted gross margin, adjusted gross margin percentage, adjusted operating expenses, adjusted operating expenses percentage, adjusted operating income, adjusted operating margin, adjusted income before income taxes, adjusted provision for income taxes, adjusted tax rate, adjusted diluted earnings per share (EPS), free cash flow, and free cash flow margin percentage.

Adjusted gross margin is defined as gross margin, determined in accordance with GAAP, excluding certain acquisition related expenses1 which are described further below. Adjusted gross margin percentage represents adjusted gross margin divided by revenue.

Adjusted operating expenses is defined as operating expenses, determined in accordance with GAAP, excluding: certain acquisition related expenses1; acquisition related transaction costs2; restructuring related expense3; and charitable foundation contribution4which are described further below. Adjusted operating expenses percentage represents adjusted operating expenses divided by revenue.

Adjusted operating income is defined as operating income, determined in accordance with GAAP, excluding: acquisition related expenses1; acquisition related transaction costs2; restructuring related expense3; and charitable foundation contribution4 which are described further below. Adjusted operating margin represents adjusted operating income divided by revenue.

Adjusted income before income taxes is defined as income before income taxes, determined in accordance with GAAP, excluding: acquisition related expenses1; acquisition related transaction costs2; restructuring related expense3; and charitable foundation contribution4which are described further below.

Adjusted provision for income taxes is defined as provision for income taxes, determined in accordance with GAAP, excluding tax related items5 which are described further below. Adjusted tax rate represents adjusted provision for income taxes divided by adjusted income before income taxes.

Adjusted diluted EPS is defined as diluted EPS, determined in accordance with GAAP, excluding: acquisition related expenses1; acquisition related transaction costs2; restructuring related expense3; charitable foundation contribution4; and tax related items5 which are described further below.

Free cash flow is defined as net cash provided by operating activities, determined in accordance with GAAP, less additions to property, plant and equipment, net. Free cash flow margin percentage represents free cash flow divided by revenue.

1Acquisition Related Expenses: Expenses incurred as a result of current and prior period acquisitions and primarily include expenses associated with the fair value adjustments to inventory, property, plant and equipment and amortization of acquisition related intangibles, which include acquired intangibles such as purchased technology and customer relationships. Expenses also include severance payments, equity award accelerations, and the fair value adjustment associated with the replacement of share-based awards related to the Linear Technology Corporation (Linear) acquisition. We excluded these costs from our non-GAAP measures because they relate to specific transactions and are not reflective of our ongoing financial performance.

2Acquisition Related Transaction Costs: Costs directly related to the proposed Maxim Integrated Products, Inc. acquisition, including legal, accounting and other professional fees as well as integration-related costs. We excluded these costs from our non-GAAP measures because they relate to a specific transaction and are not reflective of our ongoing financial performance.

3Restructuring Related Expense: Expenses incurred in connection with facility closures, consolidation of manufacturing facilities, severance, other accelerated stock-based compensation expense and other cost reduction efforts or reorganizational initiatives. We excluded these expenses from our non-GAAP measures because apart from ongoing expense savings as a result of such items, these expenses have no direct correlation to the operation of our business in the future.

4Charitable Foundation Contribution: Expenses incurred in connection with a one time contribution of registered shares of common stock to the Analog Devices Foundation. We excluded this expense from our non-GAAP measures because this expense has no direct correlation to the operation of our business in the future.

5Tax Related Items: Income tax effect of the non-GAAP items discussed above and income tax from certain discrete tax items primarily related to the resolution of prior period tax audits, income tax from certain uncertain tax positions, income tax from state valuation allowance adjustments, income tax on certain inventory intra-entity transfers, the impact of a voluntary accounting policy change and other income tax adjustments related to prior periods. We excluded the income tax benefit / provision effect of these tax related items from our non-GAAP measures because they are not associated with the tax expense on our ongoing operating results.

About Analog Devices

Analog Devices (Nasdaq: ADI) is a leading global high-performance analog technology company dedicated to solving the toughest engineering challenges. We enable our customers to interpret the world around us by intelligently bridging the physical and digital with unmatched technologies that sense, measure, power, connect and interpret. Visit http://www.analog.com.

Forward Looking Statements

This press release contains forward-looking statements, which address a variety of subjects including, for example, our statements regarding our proposed acquisition of Maxim Integrated Products, Inc. (“Maxim”); the impact of the COVID-19 pandemic on our business, financial condition and results of operations; expected revenue, operating margin, tax rate, earnings per share, and other financial results; expected market trends, market share gains, operating leverage, production and inventory levels; expected customer demand and order rates for our products and expected product offerings; product development; and marketing position. Statements that are not historical facts, including statements about our beliefs, plans and expectations, are forward-looking statements. Such statements are based on our current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: the uncertainty as to the extent of the duration, scope and impacts of the COVID-19 pandemic; political and economic uncertainty, including any faltering in global economic conditions or the stability of credit and financial markets; erosion of consumer confidence and declines in customer spending; unavailability of raw materials, services, supplies or manufacturing capacity; changes in geographic, product or customer mix; changes in export classifications, import and export regulations or duties and tariffs; changes in our or Maxim’s estimates of our respective expected tax rates based on current tax law; our ability to successfully integrate Maxim’s businesses and technologies; the risk that the expected benefits and synergies of the proposed transaction and growth prospects of the combined company may not be fully achieved in a timely manner, or at all; adverse results in litigation matters, including the potential for litigation related to the proposed transaction; the risk that we or Maxim will be unable to retain and hire key personnel; the risk associated with the timing of the closing of the proposed transaction, including the risk that the conditions to the transaction are not satisfied on a timely basis or at all or the failure of the transaction to close for any other reason or to close on the anticipated terms, including the anticipated tax treatment; the risk that any regulatory approval, consent or authorization that may be required for the proposed transaction is not obtained or is obtained subject to conditions that are not anticipated; unanticipated difficulties or expenditures relating to the transaction, the response of business partners and retention as a result of the announcement and pendency of the transaction; uncertainty as to the long-term value of our common stock; the diversion of management time on transaction-related matters; our ability to successfully integrate acquired businesses and technologies; and the risk that expected benefits, synergies and growth prospects of acquisitions may not be fully achieved in a timely manner, or at all. For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to our filings with the Securities and Exchange Commission (“SEC”), including the risk factors contained in our most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K. Forward-looking statements represent management’s current expectations and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.

Analog Devices and the Analog Devices logo are registered trademarks or trademarks of Analog Devices, Inc. All other trademarks mentioned in this document are the property of their respective owners.

ANALOG DEVICES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

(In thousands, except per share amounts)

 

 

Three Months Ended

 

Twelve Months Ended

 

Oct 31, 2020

 

Nov 2, 2019

 

Oct 31, 2020

 

Nov 2, 2019

Revenue

$

1,526,295

 

 

$

1,443,219

 

 

$

5,603,056

 

 

$

5,991,065

 

Cost of sales

503,211

 

 

501,028

 

 

1,912,578

 

 

1,977,315

 

Gross margin

1,023,084

 

 

942,191

 

 

3,690,478

 

 

4,013,750

 

Operating expenses:

 

 

 

 

 

 

 

Research and development

280,239

 

 

277,018

 

 

1,050,519

 

 

1,130,348

 

Selling, marketing, general and administrative

165,115

 

 

154,799

 

 

659,923

 

 

648,094

 

Amortization of intangibles

108,007

 

 

107,225

 

 

429,455

 

 

429,041

 

Special charges

8,051

 

 

64,788

 

 

52,337

 

 

95,659

 

Total operating expenses

561,412

 

 

603,830

 

 

2,192,234

 

 

2,303,142

 

Operating income

461,672

 

 

338,361

 

 

1,498,244

 

 

1,710,608

 

Nonoperating expense (income):

 

 

 

 

 

 

 

Interest expense

48,593

 

 

50,775

 

 

193,305

 

 

229,075

 

Interest income

(527)

 

 

(1,988)

 

 

(4,305)

 

 

(10,229)

 

Other, net

(3,704)

 

 

1,747

 

 

(2,373)

 

 

6,034

 

 

44,362

 

 

50,534

 

 

186,627

 

 

224,880

 

Income before income taxes

417,310

 

 

287,827

 

 

1,311,617

 

 

1,485,728

 

Provision for income taxes

30,784

 

 

10,133

 

 

90,856

 

 

122,717

 

Net income

$

386,526

 

 

$

277,694

 

 

$

1,220,761

 

 

$

1,363,011

 

 

 

 

 

 

 

 

 

Shares used to compute earnings per share – basic

369,284

 

 

369,051

 

 

368,633

 

 

369,133

 

Shares used to compute earnings per share – diluted

372,322

 

 

372,584

 

 

371,973

 

 

372,871

 

 

 

 

 

 

 

 

 

Basic earnings per common share

$

1.05

 

 

$

0.75

 

 

$

3.31

 

 

$

3.68

 

Diluted earnings per common share

$

1.04

 

 

$

0.74

 

 

$

3.28

 

 

$

3.65

 

ANALOG DEVICES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands)

 

 

October 31, 2020

 

November 2, 2019

Cash & cash equivalents

$

1,055,860

 

 

$

648,322

 

Accounts receivable

737,536

 

 

635,136

 

Inventories

608,260

 

 

609,886

 

Other current assets

116,032

 

 

91,782

 

Total current assets

2,517,688

 

 

1,985,126

 

Net property, plant and equipment

1,120,561

 

 

1,219,989

 

Other investments

86,729

 

 

77,324

 

Goodwill

12,278,425

 

 

12,256,880

 

Intangible assets, net

3,650,280

 

 

4,217,224

 

Deferred tax assets

1,503,064

 

 

1,582,382

 

Other assets

311,856

 

 

53,716

 

Total assets

$

21,468,603

 

 

$

21,392,641

 

 

 

 

 

Other current liabilities

$

1,364,986

 

 

$

1,208,965

 

Debt, current

 

 

299,667

 

Long-term debt

5,145,102

 

 

5,192,252

 

Deferred income taxes

1,919,595

 

 

2,088,212

 

Other non-current liabilities

1,040,975

 

 

894,357

 

Shareholders’ equity

11,997,945

 

 

11,709,188

 

Total liabilities & equity

$

21,468,603

 

 

$

21,392,641

 

 

 

 

 

ANALOG DEVICES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

 

 

Three Months Ended

 

Twelve Months Ended

 

Oct 31, 2020

 

Nov 2, 2019

 

Oct 31, 2020

 

Nov 2, 2019

Cash flows from operating activities:

 

 

 

 

 

 

 

Net income

$

386,526

 

 

$

277,694

 

 

$

1,220,761

 

 

$

1,363,011

 

Adjustments to reconcile net income to net cash provided by operations:

 

 

 

 

 

 

 

Depreciation

57,053

 

 

61,636

 

 

233,775

 

 

240,677

 

Amortization of intangibles

145,163

 

 

143,528

 

 

577,148

 

 

570,574

 

Stock-based compensation expense

36,557

 

 

37,580

 

 

149,518

 

 

150,300

 

Non-cash impairment included in special charges

 

 

9,800

 

 

 

 

14,167

 

Deferred income taxes

(71,146)

 

 

(35,809)

 

 

(113,948)

 

 

(91,253)

 

Non-cash contribution to charitable foundation

 

 

 

 

40,000

 

 

 

Other non-cash activity

(257)

 

 

14,206

 

 

5,418

 

 

40,907

 

Changes in operating assets and liabilities

118,702

 

 

149,270

 

 

(104,185)

 

 

(35,283)

 

Total adjustments

286,072

 

 

380,211

 

 

787,726

 

 

890,089

 

Net cash provided by operating activities

672,598

 

 

657,905

 

 

2,008,487

 

 

2,253,100

 

Percent of revenue

44.1

%

 

45.6

%

 

35.8

%

 

37.6

%

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

Additions to property, plant and equipment

(29,888)

 

 

(51,076)

 

 

(165,692)

 

 

(275,372)

 

Payments for acquisitions, net of cash acquired

(1,433)

 

 

(11,170)

 

 

(14,196)

 

 

(11,170)

 

Change in other assets

579

 

 

(1,512)

 

 

(635)

 

 

(6,644)

 

Net cash used for investing activities

(30,742)

 

 

(63,758)

 

 

(180,523)

 

 

(293,186)

 

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

Proceeds from debt

 

 

 

 

395,646

 

 

1,250,000

 

Early termination of debt

 

 

 

 

 

 

(1,250,000)

 

Proceeds from revolver

 

 

 

 

350,000

 

 

75,000

 

Payments on revolver

 

 

 

 

(350,000)

 

 

(75,000)

 

Debt repayments

(450,000)

 

 

(200,000)

 

 

(750,000)

 

 

(850,000)

 

Dividend payments to shareholders

(229,597)

 

 

(200,196)

 

 

(886,155)

 

 

(777,481)

 

Repurchase of common stock

(7,222)

 

 

(172,389)

 

 

(244,487)

 

 

(613,005)

 

Proceeds from employee stock plans

10,653

 

 

10,388

 

 

68,403

 

 

116,523

 

Change in other financing activities

 

 

5,087

 

 

(4,015)

 

 

(2,831)

 

Net cash used for financing activities

(676,166)

 

 

(557,110)

 

 

(1,420,608)

 

 

(2,126,794)

 

Effect of exchange rate changes on cash

(94)

 

 

(879)

 

 

182

 

 

(1,389)

 

 

 

 

 

 

 

 

 

Net (decrease) increase in cash and cash equivalents

(34,404)

 

 

36,158

 

 

407,538

 

 

(168,269)

 

Cash and cash equivalents at beginning of period

1,090,264

 

 

612,164

 

 

648,322

 

 

816,591

 

Cash and cash equivalents at end of period

$

1,055,860

 

 

$

648,322

 

 

$

1,055,860

 

 

$

648,322

 

 

 

 

 

 

 

 

 

ANALOG DEVICES, INC.

REVENUE TRENDS BY END MARKET

(Unaudited)

(In thousands)

The categorization of revenue by end market is determined using a variety of data points including the technical characteristics of the product, the “sold to” customer information, the “ship to” customer information and the end customer product or application into which our product will be incorporated. As data systems for capturing and tracking this data and our methodology evolves and improves, the categorization of products by end market can vary over time. When this occurs, we reclassify revenue by end market for prior periods. Such reclassifications typically do not materially change the sizing of, or the underlying trends of results within, each end market.

 

 

Three Months Ended

 

 

Oct 31, 2020

 

Nov 2, 2019

 

 

Revenue

 

% of revenue*

 

Y/Y %

 

Revenue

 

% of revenue*

Industrial

 

$

811,226

 

 

53%

 

9%

 

$

745,672

 

 

52%

Communications

 

312,649

 

 

20%

 

19%

 

262,808

 

 

18%

Automotive

 

229,781

 

 

15%

 

2%

 

226,057

 

 

16%

Consumer

 

172,639

 

 

11%

 

(17)%

 

208,682

 

 

14%

Total revenue

 

$

1,526,295

 

 

100%

 

6%

 

$

1,443,219

 

 

100%

 

 

 

 

 

 

 

 

 

 

 

 

 

Twelve Months Ended

 

 

Oct 31, 2020

 

Nov 2, 2019

 

 

Revenue

 

% of revenue*

 

Y/Y %

 

Revenue

 

% of revenue*

Industrial

 

$

2,987,542

 

 

53%

 

(1)%

 

$

3,011,411

 

 

50%

Communications

 

1,195,946

 

 

21%

 

(8)%

 

1,294,960

 

 

22%

Automotive

 

779,276

 

 

14%

 

(16)%

 

930,613

 

 

16%

Consumer

 

640,292

 

 

11%

 

(15)%

 

754,081

 

 

13%

Total revenue

 

$

5,603,056

 

 

100%

 

(6)%

 

$

5,991,065

 

 

100%

 

 

 

 

 

 

 

 

 

 

 

*The sum of the individual percentages may not equal the total due to rounding.

ANALOG DEVICES, INC.

RECONCILIATION OF GAAP TO NON-GAAP RESULTS

(Unaudited)

(In thousands, except per share amounts)

 

 

Three Months Ended

 

Twelve Months Ended

 

Oct 31, 2020

 

Nov 2, 2019

 

Oct 31, 2020

 

Nov 2, 2019

 

 

 

 

 

 

 

 

Gross margin

$

1,023,084

 

 

$

942,191

 

 

$

3,690,478

 

 

$

4,013,750

 

Gross margin percentage

67.0

%

 

65.3

%

 

65.9

%

 

67.0

%

Acquisition related expenses

44,741

 

 

44,822

 

 

179,374

 

 

175,266

 

Adjusted gross margin

$

1,067,825

 

 

$

987,013

 

 

$

3,869,852

 

 

$

4,189,016

 

Adjusted gross margin percentage

70.0

%

 

68.4

%

 

69.1

%

 

69.9

%

 

 

 

 

 

 

 

 

Operating expenses

$

561,412

 

 

$

603,830

 

 

$

2,192,234

 

 

$

2,303,142

 

Percent of revenue

36.8

%

 

41.8

%

 

39.1

%

 

38.4

%

Acquisition related expenses

(110,963)

 

 

(112,219)

 

 

(444,261)

 

 

(451,511)

 

Acquisition related transaction costs

(10,977)

 

 

 

 

(20,098)

 

 

 

Charitable foundation contribution

 

 

 

 

(40,000)

 

 

 

Restructuring related expense

(8,050)

 

 

(64,788)

 

 

(52,337)

 

 

(95,659)

 

Adjusted operating expenses

$

431,422

 

 

$

426,823

 

 

$

1,635,538

 

 

$

1,755,972

 

Adjusted operating expenses percentage

28.3

%

 

29.6

%

 

29.2

%

 

29.3

%

 

 

 

 

 

 

 

 

Operating income

$

461,672

 

 

$

338,361

 

 

$

1,498,244

 

 

$

1,710,608

 

Operating margin

30.2

%

 

23.4

%

 

26.7

%

 

28.6

%

Acquisition related expenses

155,704

 

 

157,041

 

 

623,635

 

 

626,777

 

Acquisition related transaction costs

10,977

 

 

 

 

20,098

 

 

 

Charitable foundation contribution

 

 

 

 

40,000

 

 

 

Restructuring related expense

8,050

 

 

64,788

 

 

52,337

 

 

95,659

 

Adjusted operating income

$

636,403

 

 

$

560,190

 

 

$

2,234,314

 

 

$

2,433,044

 

Adjusted operating margin

41.7

%

 

38.8

%

 

39.9

%

 

40.6

%

 

 

 

 

 

 

 

 

Provision for income taxes

$

30,784

 

 

$

10,133

 

 

$

90,856

 

 

$

122,717

 

Income tax effect of adjustments above

26,878

 

 

35,903

 

 

106,291

 

 

104,470

 

Income tax from certain discrete tax items

 

 

20,302

 

 

25,951

 

 

61,227

 

Adjusted provision for income taxes

$

57,662

 

 

$

66,338

 

 

$

223,098

 

 

$

288,414

 

 

 

 

 

 

 

 

 

Income before income taxes

$

417,310

 

 

$

287,827

 

 

$

1,311,617

 

 

$

1,485,728

 

Effective tax rate

7.4

%

 

3.5

%

 

6.9

%

 

8.3

%

Acquisition related expenses

155,704

 

 

157,041

 

 

623,635

 

 

626,777

 

Acquisition related transaction costs

10,977

 

 

 

 

20,098

 

 

 

Charitable foundation contribution

 

 

 

 

40,000

 

 

 

Restructuring related expense

8,050

 

 

64,788

 

 

52,337

 

 

95,659

 

Adjusted income before income taxes

$

592,041

 

 

$

509,656

 

 

$

2,047,687

 

 

$

2,208,164

 

Adjusted tax rate

9.7

%

 

13.0

%

 

10.9

%

 

13.1

%

 

 

 

 

 

 

 

 

Diluted EPS

$

1.04

 

 

$

0.74

 

 

$

3.28

 

 

$

3.65

 

Acquisition related expenses

0.42

 

 

0.42

 

 

1.68

 

 

1.68

 

Acquisition related transaction costs

0.03

 

 

 

 

0.05

 

 

 

Charitable foundation contribution

 

 

 

 

0.11

 

 

 

Restructuring related expense

0.02

 

 

0.17

 

0.14

 

 

0.26

 

Income tax effect of adjustments above

(0.07)

 

 

(0.10)

 

 

(0.29)

 

 

(0.28)

 

Income tax from certain discrete tax items

 

 

(0.05)

 

 

(0.07)

 

 

(0.16)

 

Adjusted diluted EPS*

$

1.44

 

 

$

1.19

 

 

$

4.91

 

 

$

5.15

 

* The sum of the individual per share amounts may not equal the total due to rounding.

ANALOG DEVICES, INC.

RECONCILIATION OF NET CASH PROVIDED BY OPERATING ACTIVITIES TO FREE CASH FLOW

(Unaudited)

(In thousands)

 

 

Trailing

Twelve

Months

 

Three Months Ended

 

Oct 31, 2020

 

Oct 31, 2020

 

Aug 1, 2020

 

May 2, 2020

 

Feb 1, 2020

Revenue

$

5,603,056

 

 

$

1,526,295

 

 

$

1,456,136

 

 

$

1,317,060

 

 

$

1,303,565

 

Net cash provided by operating activities

$

2,008,487

 

 

$

672,598

 

 

$

557,200

 

 

$

429,041

 

 

$

349,648

 

% of Revenue

36

%

 

44

%

 

38

%

 

33

%

 

27

%

Capital expenditures

$

(165,692)

 

 

$

(29,888)

 

 

$

(20,804)

 

 

$

(60,161)

 

 

$

(54,839)

 

Free cash flow

$

1,842,795

 

 

$

642,710

 

 

$

536,396

 

 

$

368,880

 

 

$

294,809

 

% of Revenue

33

%

 

42

%

 

37

%

 

28

%

 

23

%

ANALOG DEVICES, INC.

RECONCILIATION OF PROJECTED GAAP TO NON-GAAP RESULTS

(Unaudited)

 

 

Three Months Ending January 30, 2021

 

Reported

 

Adjusted

Revenue

$1.50 Billion

 

$1.50 Billion

 

(+/- $70 Million)

 

(+/- $70 Million)

Operating margin

29.1%

 

40.0% (1)

 

(+/-150 bps)

 

(+/-100 bps)

Nonoperating expenses

~ $43 Million

 

~ $43 Million

Tax rate

12% to 14%

 

12% to 14% (2)

Earnings per share

$0.92

 

$1.30 (3)

 

(+/- $0.10)

 

(+/- $0.10)

(1) Includes $163 million of adjustments related to acquisition related expenses and acquisition related transaction costs as previously defined in the Non-GAAP Financial Information section of this press release.

(2) Includes $23 million of tax effects associated with the adjustment for acquisition related expenses and acquisition related transaction costs noted above.

(3) Includes $0.38 of adjustments related to the net impact of $0.44 of acquisition related expenses and acquisition related transaction costs, as well as $0.06 of tax effects on those items.

(ADI WEB)

Investor Contact:

Analog Devices, Inc.

Mr. Michael Lucarelli

Sr. Director of Investor Relations

781-461-3282

[email protected]

Media Contacts:

Teneo

Ms. Andrea Calise

917-826-3804

[email protected]

Teneo

Ms. Megan Fenton

917-860-0356

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Semiconductor Hardware Manufacturing Technology Engineering

MEDIA:

Logo
Logo

Harvest Capital Credit Corporation Announces Record Date and Payment Date for Previously Deferred Dividend Payments

Harvest Capital Credit Corporation Announces Record Date and Payment Date for Previously Deferred Dividend Payments

NEW YORK–(BUSINESS WIRE)–
Harvest Capital Credit Corporation (the “Company,” “we,” or “our”) (NASDAQ: HCAP) today announced that the Board of Directors has determined a record date and payment date for the Company’s previously declared but deferred March 2020 and April 2020 monthly dividends of $0.08 per share, respectively. These deferred dividends will now be payable in a single distribution of $0.16 per share on December 29, 2020 to shareholders of record at the close of business on December 15, 2020.

“We previously deferred the record and payment dates for our March 2020 and April 2020 dividends in light of the unprecedented circumstances surrounding the COVID-19 pandemic, which was part of an overall plan to preserve liquidity,” said Joseph Jolson, Chairman and CEO. “In light of the progress the Company has made paying down its bank line of credit and to avoid the imposition of a federal excise tax on the Company’s undistributed earnings, the Board of Directors believes it is in the Company’s best interests to make this dividend distribution prior to year-end,” concluded Mr. Jolson.

About Harvest Capital Credit Corporation

Harvest Capital Credit Corporation (NASDAQ: HCAP) provides customized financing solutions to privately held small and mid-sized companies in the U.S., generally targeting companies with annual revenues of less than $100 million and annual EBITDA of less than $15 million. The company’s investment objective is to generate both current income and capital appreciation primarily by making direct investments in the form of subordinated debt, senior debt and, to a lesser extent, minority equity investments. Harvest Capital Credit Corporation is externally managed and has elected to be treated as a business development company under the Investment Company Act of 1940.

Forward-Looking Statements

This press release contains forward-looking statements subject to the inherent uncertainties in predicting future results and conditions. Any statements that are not of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. Certain factors could cause actual results and conditions to differ materially from those projected in these forward-looking statements. These factors are identified from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update such statements to reflect subsequent events, except as may be required by law.

Investor & Media Relations Contacts

Harvest Capital Credit Corporation

Joseph A. Jolson

Chairman & Chief Executive Officer

(415) 835-8970

[email protected]

William E. Alvarez, Jr.

Chief Financial Officer

(212) 906-3589

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Consulting Banking Professional Services Finance

MEDIA:

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

MARIETTA, Ohio–(BUSINESS WIRE)–
ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced the submission of a research paper describing and interpreting the results analysing the benefit of PKX-001 on human induced pluripotent stem cell (iPSC) derived retinal precursor cells transplanted to an experimental model of blindness due to retina degeneration. The paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing. Given the priority of this study, the paper has been made publically available now during the review process as a pre-print for a limited time for other stakeholders and scientists to review, discuss, or comment, here: https://www.biorxiv.org/content/10.1101/2020.11.22.393439v1

Vision loss due to degeneration of the retina, most commonly the macula, commonly appears with aging, comorbid cardiovascular conditions, genetics, or other exposures. Macular degeneration currently has no cure. It is the leading cause of reduced sharp central vision necessary for such tasks as reading or driving.

Cells transplanted without PKX-001 did not show any statistical benefits in electroretinography (ERG) or optokinetic tracking (OKT) used to measure vision function. By comparison, PKX-001 treated cells showed 3-fold greater improvement in both ERG & OKT — with more transplanted cells surviving long-term in the retina. Only PKX-001 treated cells showed maturation and integration with the host retina.

“In this experimental model of retinal degeneration, iPSC derived retinal precursor cells treated with PKX-001 remarkably improved cellular integration after transplantation to secure functional vision benefits.” – Dr. Kevin Gregory-Evans M.D., Ph.D.

PKX-001 is the designation given to the lead drug product molecule of the AAGP® family.

This study was completed by Dr. Kevin Gregory-Evans, MD, PhD, Professor of Opthalmology & the Julia Levy Leadership Chair in Macular Research at the University of British Columbia. A panel member of the California Institute of Regenerative Medicine & Canadian Institutes of Health Research. Previously, a reader in molecular ophthalmology at Imperial College London. An ophthalmologist and global leader in macular research and regenerative medicine development.

Dr. Kevin Gregory-Evans on ProtoKinetix AAGP®
Dr. Gregory-Evans Bio

Global ophthalmic therapeutics/drug market is expected to reach USD $35.7 billion by 2025, according to a new report by Grand View Research, Inc. According to market research published by iHealthcareAnalyst, the global market for organ transplantation is estimated to reach $51 billion by 2025, growing at a CAGR of 9.9% over the forecast period, driven by an aging population with increasing incidence of chronic disease, organ failures, and rising demand for transplant products, such as tissue products, immunosuppressants, and organ preservation solutions.

“Our molecule offers significant benefits to the field of regenerative medicine already. Seeing more scientific success of this magnitude is exciting as we seek further partnership for clinical trials. Our company mission and values are to benefit patients in need and I am confident AAGP is the stem cell helper to do just that.” – Clarence Smith, CEO President

See the promising research of AAGP® and results to date

Visit our new website at ProtoKinetix.com for more information and to join our email list.

About ProtoKinetix, Incorporated

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this press release includes “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included herein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. Although we believe that the expectations reflected in these forward-looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not be considered to be) guarantees of future performance. Refer to our risk factors set forth in our reports filed on Edgar. ProtoKinetix disclaims any obligation to update any forward-looking statement made here.

This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States.

Clarence E. Smith

President and chief executive officer

Telephone: 740-434-5041
Email: [email protected]

Twitter: @ProtoKinetix

KEYWORDS: Ohio United States North America

INDUSTRY KEYWORDS: Health Stem Cells Clinical Trials Pharmaceutical Optical Biotechnology

MEDIA:

Kohl’s Named to Dow Jones Sustainability Index for Third Consecutive Year

Kohl’s Named to Dow Jones Sustainability Index for Third Consecutive Year

2020 designation recognizes company’s continued commitment to sustainability efforts

MENOMONEE FALLS, Wis.–(BUSINESS WIRE)–Kohl’s (NYSE: KSS) is proud to have been named to the 2020 Dow Jones Sustainability Index (DJSI) North America by S&P Global. This marks the third year in a row the company has received the designation for its sustainability performance and environmental, social and governance (ESG) commitments.

“The DJSI’s continued recognition of Kohl’s serves as a reliable indicator of the strength of our ESG stewardship initiatives,” said Steve Thomas, Chief Risk and Compliance Officer for Kohl’s. “We believe that incorporating sustainable solutions into the way Kohl’s conducts business will help to build better futures for our customers, our associates, and their families and we are pleased to be acknowledged for these efforts.”

Launched in 1999 as one of the first global sustainability benchmarks, the DJSI measures the performance of the world’s leading companies based on financially material environmental, social, and governance factors. The DJSI helps to evaluate a company’s impact on people, communities and the planet for socially-conscious investors.

“We congratulate Kohl’s for being included in the DJSI North America. A DJSI distinction is a reflection of being a sustainability leader in your industry. With a record number of companies participating in the 2020 Corporate Sustainability Assessment and more stringent rules for inclusion this year, this sets your company apart and rewards your continued commitment to people and planet,” said Manjit Jus, Global Head of ESG Research and Data, S&P Global.

Earlier this month, Kohl’s was also recognized with a SmartWay® 2020 Excellence Award from the U.S. Environmental Protection Agency (EPA) as an industry leader in freight supply chain, environmental performance and energy efficiency. Kohl’s was one of just 17 shipper and logistics companies to receive the distinction this year, in recognition of the company’s sustainability efforts and exceptional performance moving goods in the cleanest and most energy-efficient way possible, leading to cleaner and healthier communities.

For more details about Kohl’s commitment to sustainability, please refer to the company’s 2019 CSR Report. Additional information about Kohl’s Environmental, Social, and Governance (ESG) efforts can be found on the company’s corporate website, Corporate.Kohls.com.

About Kohl’s

Kohl’s (NYSE: KSS) is a leading omnichannel retailer with more than 1,100 stores in 49 states. With a commitment to inspiring and empowering families to lead fulfilled lives, Kohl’s offers amazing national and exclusive brands, incredible savings and an easy shopping experience in our stores, online at Kohls.com and on the Kohl’s mobile app. Since its founding, Kohl’s has given more than $750 million to support communities nationwide, with a focus on family health and wellness. For a list of store locations or to shop online, visit Kohls.com. For more information about Kohl’s impact in the community or how to join our winning team, visit Corporate.Kohls.com or follow @KohlsNews on Twitter.

KSS-IR

Julia Fennelly, [email protected], 262.703.1710

 

KEYWORDS: Wisconsin United States North America

INDUSTRY KEYWORDS: Other Retail Online Retail Philanthropy Discount/Variety Department Stores Specialty Consumer Catalog Environment Fashion Retail Other Philanthropy Home Goods

MEDIA:

Logo
Logo